Michigan Medicine experimental drug reverses fatty liver in animal studies

Researchers at Michigan Medicine have developed an experimental tripeptide compound, DT-109, which has successfully reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal models. The findings, published in The Journal of Clinical Investigation, suggest the drug treats fatty liver disease by targeting the gut-liver axis rather than the liver directly.

In studies involving mice and nonhuman primates, the glycine-based tripeptide worked by repairing the intestinal barrier and reducing the growth of harmful bacteria, specifically Clostridium perfringens. This reduction in bacterial overgrowth lowers ammonia levels, preventing microbial toxins from escaping the gut and entering the bloodstream to cause liver inflammation and damage.

MASH affects approximately 7% of the global population and can progress to cirrhosis, liver cancer, or liver failure. While the results in animal models are promising, the treatment remains experimental and requires human clinical trials to determine its safety and efficacy in patients.